The SENSIGHT clinical data analytics platform combines powerful AI capabilities and access to deep, longitudinal healthcare data, empowering researchers to perform complex analysis in minutes, at a fraction of the cost of other real-world data platforms.
How SENSIGHT can deliver value
Not sure whether to run a synthetic control arm? SENSIGHT can answer that question in minutes, not months.
~120 days
of analysis saved
$600,000
per day in trial costs
$72m
in trial delays
SENSIGHT’s synthetic control arm feasibility model can eliminate ~120 days of Real-World Data sourcing and manual analysis. Given that trial delays cost at least $600,000 per day, that’s $72M in value.
Synthetic control arm feasibility is just one of the built-in AI tools available in the SENSIGHT platform.
Additional use cases
Patient characterisation
Create new patient cohorts in specific research areas across large, diverse data sets efficiently, quickly and at scale.
Patient stratification
Undertake patient stratification of cohorts to identify relevant sub-groups of patients using Sensyne’s proprietary deep clustering tools.
Synthetic control arms
Analyse the feasibility of running synthetic control arms on specific patient data sets using Sensyne’s proprietary analytics tools.
Image analysis
Reveal rich insights from radiology reports including sub populations, keyword correlations, and negative or positive sentiment.
Outcomes tracking
Analyse usage and outcomes by product or class across different health systems to understand real-world patient journeys.
Target identification
Detailed analysis of real-world patient data can increase understanding of disease progression, supporting target identification.

Deep, global clinical data
SENSIGHT enables the analysis of real-world data from Sensyne’s health system data sharing partners around the world.
The data spans several therapeutic areas and features deep, longitudinal EMR data, not shallow claims data. Sensyne’s Common Data Model makes it easier to perform analyses across all data types and sources. These datasets, combined with SENSIGHT’s built-in AI tools, provide life sciences and medical researchers with instant research and analytics capabilities.
What makes SENSIGHT different?
FAQs
SENSIGHT is a global real-world data analytics platform for the life sciences and healthcare sector, which brings together Sensyne Health’s AI expertise with our high value curated patient data set.
The platform has been built on Sensyne’s common data model, which integrates, standardises, and curates the rich longitudinal data which has been ethically sourced through our partnerships with healthcare systems. This makes it easier for researchers and clinicians to run sophisticated analysis quickly. Using a suite of AI tools to access and interrogate millions of curated patient records across multiple disease areas to get instant answers to clinical data queries.
It is also possible to run unlimited feasibility assessments and inform decisions within minutes rather than months; generate deeper insights into patient journeys and drastically reduce clinical trial costs, timelines, delays, and failure rates.
SENSIGHT was originally conceived and developed as an analytics platform for internal use by Sensyne to scale and industrialise its offering to life science companies.
Over the course of its development, we saw the value of giving many more life science companies, researchers, clinicians, and academics access to our real-world database and it is now available as a customer-facing platform over a simple web interface.
SENSIGHT is available on an individual subscriber basis to researchers across life sciences, pharmaceuticals, and healthcare providers including commercial organisations and academia who are engaged in clinical trials and other healthcare R&D.
Access to the platform will be controlled and is only available to verified researchers following a thorough online application process. Training on how to use the SENSIGHT platform will be given.
Multi-seat packages are available for larger organisation. Initially, access to SENSIGHT will be available via a concierge service, and users will be given support by a Sensyne life science data expert. Please contact the SENSIGHT team for more details of the sign-up process.
SENSIGHT is available on a subscriber basis to researchers across the life sciences and healthcare provider sectors from as little as £25,000 per user – unlike the usual 7-figure initial fee associated with competitors’ platforms that are sold on an enterprise basis.
A subscription can be applied for via the Sensyne Health Commercial representatives in your local geography. This will invoke a screening and commercial agreement/payment process. Access is granted after completion of screening protocols, signing of commercial agreements, and required user training have been completed.
Premium and Strategic Partner agreements are more complex in nature than Subscriber access, with subscriptions managed by your local Commercial representatives.
Access is granted after completion of screening protocols, signing of commercial agreements, and required user training have been completed. Once you have the subscription you can run unlimited feasibility assessments.
Premium and Strategic Partner model costs are subject to individual contracts.
Please click to view our standard terms and conditions for SENSIGHT: www.sensynehealth.com/website-policies/sensight-terms-and-conditions
It allows researchers in pharma companies to look at historical data sets and define patient cohorts to support thinking for clinical development plans (for example through the creation of synthetic control arms) or in tracking patients’ outcomes against different therapies.
SENSIGHT can also be used to support the identification of patients for clinical trials from the platforms deep longitudinal data set. It is also possible to create patient registries, where defined patient populations are followed over time to track health and disease progression, which plays an important role in monitoring the safety of medicines.
It is easy to access and simple to use.
The platform offers healthcare providers, payers, and clinicians’ sensors a cutting-edge data analytics and Machine Learning technology that allows them to really understand patients and their medical conditions in unprecedented detail.
For example, clinicians interested in looking at hospital patients with heart failure, can use SENSIGHT in conjunction with Sensyne’s SyneCHF clinical AI algorithm, to optimise care plans, and discharge timing for patients in hospital, identify patients for priority treatment and assess the risk re-admission following discharge.
It is easy to access and simple to use.
For that research, the insights derived from SENSIGHT can be used at the earliest stage of drug discovery to support target identification and validation.
The immediate access to highly curated data sets to rapidly address questions such as synthetic control arms, patient stratification and comparative real-world data/evidence are also a primary benefit of using the SENSIGHT platform.
SENSIGHT also includes imaging data, which can be analysed alongside a patient’s electronic medical record. Closer to a product launch it can be used to understand the real-world patient journey within a health system, and to support access and reimbursement strategies, including outcomes-based pricing.
The pace of digital transformation means there are increasing real-world patient sources (including electronic medical records, patient reported information, personal devices, and health apps) but accessing the data has been a challenge.
Fragmented unstructured data
Historically, the way that health systems have captured patient data has been fragmented and unstructured – stored in different formats across systems which has made it difficult to support complex RWD analyses. SENSIGHT solves this problem using a Common Data Model that integrates all data sources into one standardised, curated model. This allows sophisticated analysis of large, complex patient data sets across multiple sources.
Timelines & Cost
The unstructured nature of patient data also means it takes significant investment in time and money for clinical trial researchers to collate a trustworthy data set from many sources. SENSIGHT now makes it possible to run unlimited feasibility assessments and reach decisions within minutes rather than months; drastically reducing costs, and clinical trial delays and failure rates.
Scarcity of AI & data science talent
A further challenge has been the relative scarcity and expense of AI and data science talent available to analyse RWD. SENSIGHT puts a suite of AI tools into the hands of researchers and clinicians to enable them interrogate millions of curated, longitudinal real-world patient data records across multiple disease areas.
Compliance & governance
Finally, Sensyne’s compliance with all appropriate ethical oversight and information governance standards (including conformance with NHS principles, GDPR and the UK Data Protection Act 2018) ensures that patient data and confidentiality is protected. This builds trust with the providers of that data – namely our partner NHS Trusts and Healthcare Systems in the US.
SCAs are a new methodology in clinical trials. In an SCA the experimental arm is conducted as normal, but the control arm is replaced or supported by an additional data arm, which takes data from the electronic patient records of a comparable group of real-world patients.
SCAs can reduce the time and cost it takes to conduct a randomised controlled trial, as well as reducing the number of patients needed - saving valuable time and resources. Recruitment for control arms is a significant factor in the cost and duration of clinical trials and ultimately new drug development. . In some cases, such as for very rare diseases or where treatment options are limited, the use of SCAs can also be more ethical as all patients enrolled in the trial can benefit from the proposed treatment (as opposed to being given a placebo).
SENSIGHT allows researchers to quickly assess the feasibility of running a synthetic control arm, and work with a deeply curated patient cohort to match desired characteristics for trials in major disease areas. This helps reduce the costs and timeline and minimises delays and failure rate due to patient data not being good enough, or not being able to identify the right patients or recruit them in large enough volumes.
The power of the platform lies in the breadth and depth of its data. SENSIGHT accesses deep curated data from hospital electronic patient records and other hospital data bases – includes detailed information on demographics, vital signs, diagnosis, treatment, medication, the full suite of biochemical and genetic tests and procedures.
This is significantly deeper than what would be routinely accessed through Hospital Episode Statistics in the UK or claims data in the US. Alternative providers of real-world data routinely work with this type of shallower data sets. SENSIGHT is also differentiated by the fact that it covers multiple disease areas and includes imaging data, which can be analysed alongside a patient’s electronic medical record.
The data is curated according to a proprietary common data model that we have developed in-house, which enables us to combine data sets from different trusts and ensure that all data features are aligned. This enables us to the provide an in-depth statistical characterisation of the data.
Sensyne has a real-world dataset of 48.3 million de-identified patient records. This is made up of 26.3 million de-identified patient data records (12.9 million in UK and 13.4 million patients in the US) which span the care continuum and includes longitudinal EHR sourced data records, together with a further 22.0 million available in the US through our teaming agreement with OMNY Health. An additional 42 million clinical trial data records are also available through our partnership with Phesi.
We have built our deep clinical dataset across multiple disease areas through our ethical data sharing partnerships with healthcare organisations in the UK & US.
By 2024 we aim to have over 100m patient records in the SENSIGHT platform, which can be accessed by clinicians, life sciences organisations and academics to power their research.
Major disease areas on SENSIGHT include chronic kidney disease; Heart Failure; Hepatitis B, Haematological blood cancers; Myeloproliferative Neoplasms (MPNs); Multiple Myeloma; Motor Neurone Disease, Prostate Cancer and Stroke. By summer 2022 our goal is for the SENSIGHT platform to encompass a total of 15 disease areas with the addition lung, breast, liver, pancreatic, ovarian, and renal cancers. By the end of 2024 Sensyne is aiming to have contracts in place that will provide direct access to 100 million patient records covering all major disease areas.
The patient data record database is expected to grow significantly over the next three years. By the end of 2024 Sensyne aims to have contracts in place that will provide direct access to 100 million curated patient records covering all major disease areas.
SENSIGHT will also include the ability to process data sources in multiple languages.
Yes. SENSIGHT is supported by a rigorous information governance framework, and all data is de-identified and anonymised. The system does not give direct access to patient data, in line with the Company’s strict policy of never sharing patient data and never selling patient data. Only those in accredited companies and organisations will be given access to subscriptions, and patient data is not accessed directly. All users will be expected to undergo training before they are allowed to use the SENSIGHT platform.
No. SENSIGHT is not available in a distributed model to support queries or research on behalf of others or other companies/institutions outside of the one Subscribers work for.
Shared access to research will only be permitted within the same accredited organisation, institution or company that has the relevant Commercial model in place.
Yes. SENSIGHT will allow screened and accredited users to only download results of data that they are entitled and permitted to view/consume.
Yes. SENSIGHT and the underlying datasets will benefit from the latest Microsoft cloud technologies. With data curated, stored, processed, and analysed all in the cloud, the physical limitations of on-premises data management and storage are removed. This will permit individual users who subscribe to the SENSIGHT service and have met all required regulatory and training requirements to access the platform securely from any location, permitted they meet the required security posture of that registered user. Secure tokens, MFA, etc. may be invoked dependent on the physical location of the user/device.
No. SENSIGHT is not available in a distributed model to support queries on behalf of others or other companies/institutions outside of the one Subscribers work for. Subscribers will be screened according to strict governance protocols. Only industry professionals will be given access, having provided sufficient proof that they are conducting research on behalf of accredited organisations, institutions, or companies.
SENSIGHT is covered by strict governance protocols and operates within the highest ethical standards and a rigorous governance framework to ensure that all data is protected, and that only insights from the data, not patient records, are available.
Users will be monitored to ensure the platform is only being used for legitimate research, and anyone found to be misusing the platform will be removed. Sensyne will be alerted if accredited users share their log-in details with others. All users will be expected to undergo training before they are allowed to use the SENSIGHT platform.
Please contact professionalservices@sensynehealth.com